These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 26724667)

  • 1. Usefulness and pitfalls of F-18-FDG PET/CT for diagnosing extramedullary acute leukemia.
    Zhou WL; Wu HB; Wang LJ; Tian Y; Dong Y; Wang QS
    Eur J Radiol; 2016 Jan; 85(1):205-210. PubMed ID: 26724667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Li H; Xu C; Xin B; Zheng C; Zhao Y; Hao K; Wang Q; Wahl RL; Wang X; Zhou Y
    Theranostics; 2019; 9(16):4730-4739. PubMed ID: 31367253
    [No Abstract]   [Full Text] [Related]  

  • 4. Utility of F-18 FDG PET/CT on the evaluation of primary bone lymphoma.
    Wang LJ; Wu HB; Wang M; Han YJ; Li HS; Zhou WL; Wang QS
    Eur J Radiol; 2015 Nov; 84(11):2275-9. PubMed ID: 26388466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of
    Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
    Kawata S; Imaizumi M; Kako Y; Oku N
    Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT in patients with adult-onset Still's disease.
    Dong MJ; Wang CQ; Zhao K; Wang GL; Sun ML; Liu ZF; Xu L
    Clin Rheumatol; 2015 Dec; 34(12):2047-56. PubMed ID: 25711875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of 18F-FDG PET/CT imaging for evaluation of patients with primary splenic lymphoma.
    Karunanithi S; Sharma P; Roy SG; Vettiyil B; Sharma A; Thulkar S; Bal C; Kumar R
    Clin Nucl Med; 2014 Sep; 39(9):772-6. PubMed ID: 25036015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of 18F-FDG PET/CT in the detection of neurolymphomatosis.
    Zhou WL; Wu HB; Weng CS; Han YJ; Wang M; Huang S; Wang QS
    Nucl Med Commun; 2014 Nov; 35(11):1107-11. PubMed ID: 25144562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
    Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
    Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing POEMS Syndrome with 18F-FDG PET/CT.
    Pan Q; Li J; Li F; Zhou D; Zhu Z
    J Nucl Med; 2015 Sep; 56(9):1334-7. PubMed ID: 26182964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Missed causative tumors in diagnosing tumor-induced osteomalacia with (18)F-FDG PET/CT: a potential pitfall of standard-field imaging.
    Kaneuchi Y; Hakozaki M; Yamada H; Hasegawa O; Tajino T; Konno S
    Hell J Nucl Med; 2016; 19(1):46-8. PubMed ID: 26929940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.